Nevertheless, subsequent studies demonstrate that patients with sensitizing mutations of EGFR gene are more responsive to gefitinib or erlotinib compared with patients without such mutations [37–39], which leads to the administration of EGFR inhibitors for precision cancer therapy. Here, EGFR is linked to cancer.